New Agar Medium for the Isolation and Testing Susceptibility of Mycobacterium Tuberculosis Against Drugs
Tech ID:
00-05
Summary - Scientists at National Jewish Health have developed a new agar medium for the isolation of M. tuberculosis from patients. The medium can also be used for testing susceptibility of M. tuberculosis against various drugs such as pyrazinamide.
Potential Applications
- Isolation of M tuberculosis from patients specimens
- Sub-cultivation of M. tuberculosis pure cultures
- Direct and indirect susceptibility testing.
Advantages of Invention
- The medium can be used in regular incubators (without supplemental CO2)
- The medium can be used at pH 6.0
- The medium can be used for a test with pyrazinamid
- The medium is using animal serum (bovine serum for example) instead of OADC
- The medium is less expensive to produce
- Pyrazinamide test can be performed more easily and faster
State of Development - The medium has been successfully tested to isolate M. tuberculosis and for susceptibility with pyrazinamide
Further R&D Required - Susceptibility testing against other drugs.
Licensing Potential - Available for licensing.
Patent Status - U.S. Patents #6,579,694and #6,951,733
Inventors -
Heifets L, PhD and Sanchez T.
Publication
- Heifets L. & Sanchez T. J Clin Microbiol. 2000 Apr; 38(4):1498-501. PMID: 10747133
For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: (303) 398-1262
Fax: (303) 270-2352
HilaireE@njhealth.org
